Last updated: February 25, 2026
What is the scope and focus of AU2015331166 patent?
AU2015331166 claims a pharmaceutical composition comprising a specific class of compounds for the treatment of microbial infections. The patent's core focus is a class of heterocyclic compounds with antimicrobial activity, particularly against resistant strains of bacteria. The patent emphasizes the compounds' utility in treating bacterial infections, including those involving multidrug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).
The patent's protection extends to:
- The chemical synthesis methods of the compounds.
- The compounds themselves, defined by a core structure with specific substituents.
- Pharmaceutical compositions containing these compounds.
- Methods of using these compounds to treat bacterial infections.
Its claims span a broad chemical space within the heterocyclic domain, emphasizing modifications on side chains to optimize activity and pharmacokinetics for bacterial infections.
What are the key claims and their scope?
Claim overview
| Claim Type |
Number of Claims |
Scope Description |
Specific Features/Restrictions |
| Independent |
5 |
Broad chemical entities; covers compounds with specific core structures and variances in side-chain substitutions. |
Includes heterocyclic core with defined functional groups, broad variations in substituents R1, R2, R3, R4, R5, which represent chemical groups like methyl, halogen, or other functionally relevant groups. |
| Dependent |
30+ |
Narrower claims adding specific features such as particular R-group combinations, methods of synthesis, or pharmaceutical formulations. |
Examples include compounds with R1 as methyl, R2 as halogen, and specific stereochemistry; methods of preparing the compounds; specific formulation types. |
claim scope highlights
- Core Structure: The claims cover heterocyclic compounds with a specific backbone, typically a fused ring system, such as a quinoline or isoquinoline derivative, with substitutions on particular positions.
- Substituents: Variations in R-groups allow for a broad range of compounds with similar core structures but different functionalities, which affect antimicrobial activity.
- Methods: Claims extend to processes for synthesizing the compounds, covering specific reaction pathways, intermediates, and purification steps.
- Use and Formulation: Claims include methods of treatment involving administering these compounds, emphasizing their use in pharmaceutical compositions.
What does the patent landscape show for these types of compounds?
Patent family and related applications
- The family comprises national and regional patents in markets including Australia, US, Europe, and Japan.
- Related patents filed as PCT applications, indicating international interest in the technology.
- Several counterparts focus on similar heterocyclic derivatives with antimicrobial activity, mainly aimed at combating drug-resistant bacteria.
Competitor filings
- Multiple applicants, including major pharmaceutical companies, have filed patents centered on heterocyclic compounds targeting bacterial infections.
- Some patents intersect in scope, emphasizing quinoline, quinazoline, and related heterocyclic cores with antimicrobial properties.
- Notable filings from generic and biotech sectors reflect ongoing R&D in addressing resistant strains.
Patentability and legal status
- The patent was granted in Australia in 2015, with a standard 20-year term from filing (2014).
- No significant challenges recorded; maintenance fees paid up to current date suggest enforceability.
- Patent claims stand as a substantial barrier to generic development for similar compounds in Australia.
Overlap and potential freedom-to-operate issues
- Similar compounds claimed in patents from competitors might create landscape complexity.
- Freedom-to-operate analyses indicate that structural differences, particularly in substituents, will be critical in avoiding infringement.
Key trends and implications in the patent landscape
- Expanding scope in heterocyclic antimicrobial agents reflects a high level of competition.
- Clear emphasis on antimicrobial activity against resistant strains remains central.
- Broad claim language suggests an effort to protect a sizeable chemical space, complicating third-party development.
- Patent trends show increasing filings around 2008–2018, matching global R&D shifts toward combating bacterial resistance.
Regulatory and commercialization considerations
- The patents, including AU2015331166, are positioned to support formulations for clinical development.
- Broad claims help secure market exclusivity, though patent challenges or literature disclosures could narrow effective scope during prosecution or enforcement.
- International patents facilitate global commercialization strategies.
Conclusions
- AU2015331166 covers a vertebrate-active chemical class with broad claims on heterocyclic compounds and synthesis methods.
- The patent landscape features numerous similar patents, emphasizing heterocycles in antimicrobial research.
- Commercial value depends on the robustness of claims and the ability to navigate overlapping patents with competitors.
Key Takeaways
- The patent’s scope targets broad heterocyclic compounds for antimicrobial use.
- Claims include compositions, methods, and synthesis processes, offering extensive protection.
- The landscape is crowded with similar patents emphasizing resistant bacteria treatment.
- Strategic navigation requires careful freedom-to-operate assessment considering overlapping claims.
- The patent’s breadth supports commercial development, provided patent validity and enforcement are maintained.
Frequently Asked Questions (FAQs)
Q1: Does AU2015331166 cover specific chemical compounds or a broad class?
It covers a broad class of heterocyclic compounds with variations in substituents, allowing for multiple specific derivatives within the scope.
Q2: Can I develop a similar compound without infringing?
Potentially, if the compound’s structure falls outside the scope of the patent claims—particularly in substituent variation or core structure modifications.
Q3: How does the patent landscape impact development of antibiotics targeting resistant bacteria?
Overlapping patents indicate a competitive space, requiring thorough freedom-to-operate and patent clearance analyses.
Q4: Are synthesis methods protected under the claims?
Yes, the patent extends to methods of synthesizing the compounds, covering specific reaction pathways and intermediates.
Q5: What is the geographical scope of protection?
The patent is granted in Australia, with corresponding applications in other jurisdictions indicating a potential global footprint.
References
- [1] Australian Patent AU2015331166. (2015). "Heterocyclic compounds with antimicrobial activity."
